Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Astellas Pharma Inc
(OP:
ALPMF
)
9.848
UNCHANGED
Streaming Delayed Price
Updated: 11:40 AM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
9.848
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
9.848
Today's Range
9.848 - 9.848
52wk Range
8.405 - 12.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Is Taysha Gene Therapies Stock Falling Friday?
October 17, 2025
Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.
Via
Benzinga
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
August 12, 2025
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for cisplatin therapy.
Via
Benzinga
Performance
YTD
-0.2%
-0.2%
1 Month
-12.8%
-12.8%
3 Month
+3.2%
+3.2%
6 Month
-2.7%
-2.7%
1 Year
-10.9%
-10.9%
More News
Read More
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study
July 10, 2025
Via
Benzinga
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre
March 18, 2025
Via
Benzinga
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
February 11, 2025
Via
Benzinga
Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise
January 03, 2025
Via
Benzinga
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
December 31, 2024
Via
Benzinga
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
October 16, 2024
Via
Benzinga
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
August 05, 2024
Via
Benzinga
Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
May 17, 2024
Via
Benzinga
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
October 05, 2023
Via
Benzinga
Why Is Seagen Stock Trading Higher Today?
September 22, 2023
Via
Benzinga
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
September 20, 2023
Via
Benzinga
Why Shares of Adaptive Biotechnologies Jumped This Week
June 16, 2023
Via
The Motley Fool
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
June 08, 2023
Via
Benzinga
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
June 01, 2023
Via
TheNewswire.com
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
June 01, 2023
Via
News Direct
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
May 30, 2023
Via
Benzinga
Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
May 15, 2023
Via
Benzinga
Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
May 15, 2023
Via
Benzinga
Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
May 01, 2023
Via
Benzinga
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
May 01, 2023
Via
Benzinga
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
April 04, 2023
Via
Benzinga
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
March 28, 2023
Via
Benzinga
Japanese Government Urges China To Release Astellas Pharma's Employee
March 27, 2023
Via
Benzinga
Frequently Asked Questions
Is Astellas Pharma Inc publicly traded?
Yes, Astellas Pharma Inc is publicly traded.
What exchange does Astellas Pharma Inc trade on?
Astellas Pharma Inc trades on the OTC Traded
What is the ticker symbol for Astellas Pharma Inc?
The ticker symbol for Astellas Pharma Inc is ALPMF on the OTC Traded
What is the current price of Astellas Pharma Inc?
The current price of Astellas Pharma Inc is 9.848
When was Astellas Pharma Inc last traded?
The last trade of Astellas Pharma Inc was at 10/17/25 11:40 AM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today